CSL to Complete Haemonetics Platform Rollout in US Plasma Centers by End 2027
HAE has more than doubled off its 52-week low of $48.17.
Summary
CSL is expanding its relationship with Haemonetics, committing to complete the rollout of Haemonetics' platform in its U.S. plasma centers by the end of 2027. CSL may utilize Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposables in the United States, and currently anticipates that the transition will occur at all of its current U.S. plasma collection centers. The scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement, and implementation details are still to be determined by CSL and Haemonetics. This builds upon the non-exclusive supply agreement for NexSys PCS devices and disposables that Haemonetics announced with CSL Plasma in an 8-K filing on August 18th. The transition to Haemonetics' platform is expected to increase plasma collection network efficiency, solidifying a significant strategic partnership for Haemonetics. Haemonetics will provide an update on the supply agreement's fiscal 2027 financial impact during its second-quarter earnings call in November 2026, and is not updating its previously issued fiscal 2027 guidance at this time.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Haemonetics will provide an update on the supply agreement's fiscal 2027 financial impact during its second-quarter earnings call in November 2026.
- Rollout Scope — CSL may utilize Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposables in the United States. CSL currently anticipates that the transition will occur at all of CSL's current U.S. plasma collection centers.
- Implementation — The scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement. Implementation details are still to be determined by CSL and Haemonetics.
- Guidance — Haemonetics is not updating its previously issued fiscal 2027 guidance at this time.
All 5 details
- CSL may utilize Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposables in the United States.
- CSL currently anticipates that the transition to Haemonetics' devices and disposables will occur at all of CSL's current U.S. plasma collection centers.
- The scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement.
- Implementation details for the rollout are still to be determined by CSL and Haemonetics.
- Haemonetics is not updating its previously issued fiscal 2027 guidance at this time.
At the time of this announcement, HAE was trading at $101.71 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $48.17 to $110.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.